Factors Associated with Preferred Pre-Exposure Prophylaxis Dosing Regimen Among Men Who Have Sex with Men in Real-World Settings: A Mixed-Effect Model Analysis.
Event-driven
HIV prevention
MSM
On-demand
PrEP
Sexual behavior
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
pubmed:
10
7
2020
medline:
5
2
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
When provided with both choices of pre-exposure prophylaxis (PrEP) in MSM, men may choose to use either method based on their sexual practice. The study objective was to describe the switches between dosing regimens and identify factors that predict choice of a dosing regimen among MSM. We performed a multi-center, observational, prospective PrEP cohort study conducted at three study sites in Taiwan between January 2018 and March 2019. A total of 215 participants made 469 visits. In half of the visits (49.7%), participants reported using on-demand PrEP. There were 36 regimen switches: 20 from daily to on-demand and 16 from on-demand to daily. Among 28 participants who switched regimens, 22 switched regimens once and 6 switched more than once. The frequency of condomless anal sex and a history of post-exposure prophylaxis use were associated with taking PrEP on-demand (p < 0.05). PrEP adherence intervention should be tailored specifically to sexual behavior to increase adherence to PrEP. Cuando se les proporcionan ambas opciones de la profilaxis pre-exposición (PrEP) en HSH, los hombres pueden elegir usar cualquiera de los métodos según su práctica sexual. El objetivo del estudio fue describir los cambios entre los regímenes de dosificación e identificar los factores que predicen la elección del régimen de dosificación entre los HSH. Realizamos un estudio de cohorte prospectivo, observacional y multicéntrico de la PrEP realizado en tres sitios de estudio en Taiwán entre enero de 2018 y marzo de 2019. Un total de 215 participantes contribuyeron con 469 visitas. En la mitad de las visitas (49.7%), los participantes informaron haber usado PrEP a pedido. Hubo 36 cambios de régimen: 20 de diario a pedido y 16 de pedido a diario. Entre los 28 participantes que cambiaron de régimen, 22 cambiaron de régimen una vez y 6 cambiaron más de una vez. La frecuencia del sexo anal sin condón y cualquier uso previo de la PEP fueron asociados con la toma de la PrEP a pedido (p < .05). La intervención de adherencia a la PrEP debe adaptarse específicamente al comportamiento sexual para aumentar la adherencia a la PrEP.
Autres résumés
Type: Publisher
(spa)
Cuando se les proporcionan ambas opciones de la profilaxis pre-exposición (PrEP) en HSH, los hombres pueden elegir usar cualquiera de los métodos según su práctica sexual. El objetivo del estudio fue describir los cambios entre los regímenes de dosificación e identificar los factores que predicen la elección del régimen de dosificación entre los HSH. Realizamos un estudio de cohorte prospectivo, observacional y multicéntrico de la PrEP realizado en tres sitios de estudio en Taiwán entre enero de 2018 y marzo de 2019. Un total de 215 participantes contribuyeron con 469 visitas. En la mitad de las visitas (49.7%), los participantes informaron haber usado PrEP a pedido. Hubo 36 cambios de régimen: 20 de diario a pedido y 16 de pedido a diario. Entre los 28 participantes que cambiaron de régimen, 22 cambiaron de régimen una vez y 6 cambiaron más de una vez. La frecuencia del sexo anal sin condón y cualquier uso previo de la PEP fueron asociados con la toma de la PrEP a pedido (p < .05). La intervención de adherencia a la PrEP debe adaptarse específicamente al comportamiento sexual para aumentar la adherencia a la PrEP.
Identifiants
pubmed: 32643021
doi: 10.1007/s10461-020-02964-5
pii: 10.1007/s10461-020-02964-5
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-258Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 108-2636-B-006-004
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 109-2636-B-006-004
Références
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med. 2010;363(27):2587–99.
doi: 10.1056/NEJMoa1011205
Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New Engl J Med. 2012;367(5):399–410.
doi: 10.1056/NEJMoa1108524
Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New Engl J Med. 2012;367(5):423–34.
doi: 10.1056/NEJMoa1110711
Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2013;381(9883):2083–90.
doi: 10.1016/S0140-6736(13)61127-7
Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. New Engl J Med. 2015;373(23):2237–46.
doi: 10.1056/NEJMoa1506273
McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (London, England). 2016;387(10013):53–60.
doi: 10.1016/S0140-6736(15)00056-2
World Health Organization. Technical brief: what’s the 2+ 1+ 1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO’s recommendation on oral PrEP. Geneva: World Health Organization; 2019.
Nichols BE, Boucher CA, van der Valk M, Rijnders BJ, van de Vijver DA. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. Lancet Infect Dis. 2016;16(12):1423–9.
doi: 10.1016/S1473-3099(16)30311-5
Tan DHS, Hull MW, Yoong D, et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017;189(47):E1448–E14581458.
doi: 10.1503/cmaj.170494
British HIV Association. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. London: British HIV Association; 2018.
Chu IYH, Ku SWW, Li CW, et al. Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention-2018 update. J Microbiol Immunol Infect. 2020;53(1):1–10.
doi: 10.1016/j.jmii.2019.09.003
European AIDS Clinincal Society (EACS). European Guidelines for treatment of HIV-positive adults in Europe Guidelines. Brussels: European AIDS Clinincal Society (EACS); 2018.
Wright E, Grulich A, Roy K, et al. Australasian Society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad. 2017;3:168–84.
doi: 10.1016/S2055-6640(20)30338-1
Mannheimer S, Hirsch-Moverman Y, Franks J, et al. Factors associated with sex-related pre-exposure prophylaxis adherence among men who have sex with men in New York City in HPTN 067. JAIDS. 2019;80(5):551.
pubmed: 30865051
Cornelisse VJ, Lal L, Price B, et al. Interest in Switching to on-demand HIV pre-exposure prophylaxis (PrEP) among Australian users of daily PrEP: an online survey. Open forum Infect Dis. 2019;6(7):ofz287.
doi: 10.1093/ofid/ofz287
Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–e410410.
doi: 10.1016/S2352-3018(17)30089-9
Noret M, Balavoine S, Noret M, et al. Daily or on demand oral TDF/FTC for HIV pre-exposure prophylaxis: experience from an hospital-based clinic in France. AIDS (London, England). 2018;32(15):2161–9.
doi: 10.1097/QAD.0000000000001939
Hoornenborg E, Achterbergh RC, van der Loeff MFS, et al. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. J Int AIDS Soc. 2018;21(3):e25105.
doi: 10.1002/jia2.25105
Taiwan Centers for Disease control. Statistics of HIV/AIDS monthly report. Taipei: Taiwan Centers for Disease control; 2019.
PrEPWatch. PrEP in practice-country updated: PrEPWatch. 2019. https://www.prepwatch.org/in-practice/country-updates/ . Accessed 9 Sept 2019.
Australian Bureau of Statistics Australian Demographic Statistics: Australian Bureau of Statistics. 2019. https://www.abs.gov.au/ausstats/abs@.nsf/0/D56C4A3E41586764CA2581A70015893E?Opendocument . Accessed 9 Dec 2019.
Wu H, Strong C, Ku S, et al. Syphilis acquisition and dosing schedule for pre-exposure prophylaxis (PrEP) users in Taiwan PrEP demonstration project. Poster presented at the 22nd International AIDS Conference Amsterdam, the Netherlands; 2018.
Holloway I, Dougherty R, Gildner J, et al. PrEP uptake, adherence, and discontinuation among California YMSM using geosocial networking applications. JAIDS. 2017;74(1):15.
pubmed: 27552158
Lee YC, Chang SY, Lin KY, et al. Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey. BMJ Open. 2017;7(10):e015142.
doi: 10.1136/bmjopen-2016-015142
National Institute for Health and Care Excellence. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil). London: National Institute for Health and Care Excellence; 2019.
National Statistics of Taiwan. Per capita GDP in 2018: National Statistics of Taiwan; https://eng.stat.gov.tw/point.asp?index=1 . Accessed 9 Sept 2019.
The World Bank. GDP per capita: The World Bank; https://data.worldbank.org/indicator/NY.GDP.PCAP.CD . Accessed 9 Sept 2019.
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.
doi: 10.1001/archinte.166.10.1092
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.
doi: 10.1046/j.1525-1497.2001.016009606.x
Vonesh EF, Carter RL. Mixed-effects nonlinear regression for unbalanced repeated measures. Biometrics. 1992;48:1–17.
doi: 10.2307/2532734
Molina JM, Ghosn J, Béniguel L, et al. Incidence of HIV-infection in the ANRS Prevenir study in Paris region with daily or on-demand PrEP with TDF/FTC. AIDS 2018; Amsterdam, 2018.
Zimmermann HM, Eekman SW, Achterbergh RC, et al. Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxisa qualitative analysis. J Int AIDS Soc. 2019;22(10):e25389.
doi: 10.1002/jia2.25389
Reyniers T, Nostlinger C, Laga M, et al. Choosing between daily and event-driven pre-exposure prophylaxis: results of a belgian PrEP demonstration project. J Acquir Immune Defic Syndr. 2018;79(2):186–94.
doi: 10.1097/QAI.0000000000001791
Hoornenborg E, Coyer L, Achterbergh RC, et al. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study. Lancet HIV. 2019;6(7):e447–e45555.
doi: 10.1016/S2352-3018(19)30136-5
Underhill K, Guthrie KM, Colleran C, et al. Temporal fluctuations in behavior, perceived HIV risk, and willingness to use pre-exposure prophylaxis (PrEP). Arch Sex Behav. 2018;47(7):2109–21.
doi: 10.1007/s10508-017-1100-8
Patel VV, Ginsburg Z, Golub SA, et al. Empowering with PrEP (E-PrEP), a peer-led social media–based intervention to facilitate HIV preexposure prophylaxis adoption among young black and latinx gay and bisexual men: protocol for a cluster randomized controlled trial. JMIR Res Protoc. 2018;7(8):e11375.
doi: 10.2196/11375
Dehlin JM, Stillwagon R, Pickett J, Keene L, Schneider JA. # PrEP4Love: an evaluation of a sex-positive HIV prevention campaign. JMIR Public Health Surveill. 2019;5(2):e12822.
doi: 10.2196/12822
Lachowsky NJ, Tattersall TL, Sereda P, et al. Community awareness of, use of and attitudes towards HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in Vancouver, Canada: preparing health promotion for a publicly funded PrEP program. Sexual Health. 2019;16(2):180–6.
pubmed: 31040001
Australian Federation of AIDS Organisations (AFAO). We can end HIV by 2020: Australian Federation of AIDS Organisations (AFAO). https://endinghiv.org.au . Accessed 9 Sept 2019.
Vaccher SJ, Gianacas C, Templeton DJ, et al. Baseline preferences for daily, event-driven, or periodic HIV pre-exposure prophylaxis among gay and bisexual men in the PRELUDE demonstration project. Front Public Health. 2017;5:341.
doi: 10.3389/fpubh.2017.00341
Siguier M, Mera R, Pialoux G, et al. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine. J Antimicrob Chemother. 2019;74(9):2752–8.
doi: 10.1093/jac/dkz220
Closson EF, Mitty JA, Malone J, Mayer KH, Mimiaga MJ. Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. AIDS Care. 2018;20(2):191–8.
doi: 10.1080/09540121.2017.1360992
Ku S, Strong C, Huang P, et al. Characteristics of men who have sex with men engaging "Chemsex" ands its prevalence in Taiwan: 2017 Hornet/Heart Survey. Poster presented at the 22nd International AIDS Conference Amsterdam, the Netherlands; 2018.